Obesity Drugs in Development: A brief overview of the pipeline

Obesity and its causes are the focus of extensive research evaluating new therapeutic targets. Get an at-a-glance update on progress and FDA approvals during 2021

Pharmacologic options for obesity management have been limited, but increased understanding of the pathophysiology of the disease of obesity has given rise to promising drug targets and novel therapeutic strategies, according to the authors of a recent review in Endocrine Reviews.

The authors point to a broad range of systems and tissues being investigated as sites of targets for pharmacotherapy including the central nervous system, gastrointestinal hormones, adipose tissue, kidney, liver, and skeletal muscle.

Scroll through the slides below for concise summaries of new obesity drugs under investigation and coming into play in 2021.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
Related Content
© 2023 MJH Life Sciences

All rights reserved.